to will happy our X our to discuss I'm XXXX. for for everyone. provide XXXX revised afternoon, year. I third our Good of guidance of financial review financial and the the guidance Carl. initial more in quarter you, Thank detail the balance results and for revenue also months
on Let's start Slide XX.
our GAAP numbers. As revenues reported from you this have Beginning with of seen $XXX.X million afternoon, press represented growth QX XXXX. in our QX XXX% release of
Our million interests operating the for noncontrolling margin XX%. net After in income was the before Operating $XXX.X amount $XXX.X on gain to Income was quarter XX%. backing the of our the of Protein our attributable third was from segment, quarter. out operations XXXX. the sale GAAP was Detection margin million
XX. non-GAAP QX was for represents XXXX. This $XX.X million measure for increase $XXX Turning EBITDA, QX a Slide compared to Adjusted year-over-year. XXX% million to
margin QX EBITDA was XX% from QX our Production volume margin business. up Our our our to Acid the Slide On adjusted XX% increase was margin Nucleic adjusted in and XXXX improvements overall from with sales consistent primarily recent The driven by increases XXXX. year-over-year in XX. most EBITDA in and XX%,
diluted So diluted basic EPS, fully adjusted we and present EPS. fully EPS
Our income net EPS Class basic attributable shares is average divided Class shares. the A by A weighted our to
And weighted B and and other interest fully both fully weighted prior awards. divided both by by the securities such and the equals dilutive adjusted shares income to shares diluted EPS net Our Class securities. average adjusted dilutive net divided A of as and EPS other diluted B for income equals Class A average noncontrolling equity our
adjusted EPS Our $X.XX diluted basic $X.XX, diluted share. fully quarter per and the and were was EPS for while $X.XX
Slide continued to and have balance XX, sheet flows. an on As we have see strong now can exceptionally you cash
which at September cash $XXX GAAP Our XXXX. are XX, cash metrics, equivalents, and totaled million
have Our We strong for EBITDA expenditures. unamortized a times on capital to $XXX.X EBITDA million. X.X of gross $XXX robust net the we debt low cash million At adjusted EBITDA to prior issuance define free times ratio quarter, gross cash the $XXX.X in million, performance are costs, led measure $XXX.X a debt of flow free to as quarter zero had debt cash and and end with flow the we adjusted long-term non-GAAP adjusted XX-month below less of in million adjusted trailing EBITDA adjusted a record basis.
customer the flows strong long-term financial make and needs sheet, balance will to robust contribute capacity inorganic and innovation, cash address Our debt flexibility continued capacity, both overall to investments growth. and that us organic drive give build
quarter, financial insights I'll segment provide to XX. Slide Now more businesses some into our turn to performance for the
value our customers in EBITDA the the revenues continues of our of as in well million efficiencies this unique Nucleic as company's facility. Acid of Production business XXXX. XX% As manufacturing to the the of adjusted of fueled Production Carl Wateridge reflect at third approximately the operations growth $XXX in EBITDA Nucleic the revenue represented quarter significant for mentioned the generated portion margin million quarter. earlier, business adjusted revenue most our in the state-of-the-art Acid scale the vaccine COVID-XX quarter in total and the from third XX% products from The CleanCap quarter. $XXX.X were
in million quarter. company's third and our segment's of quarter. of from Our comprised our number Safety and portfolio business of and This the driven this the overall depth increasing X% Testing by all the the which services. in and of products, biologics the revenue Cygnus contributed product programs Revenues biosimilar branded development demand drug were business, virtually strength $XX.X was Biologic
core HCP in segment. demands our growth which a service X-month of strong on And the kits, only million business $XX.X revenue Biologic period. a demonstrates from Safety year capabilities reflects Testing not quarter. delivered than and adjusted XX.X% offerings, within Testing our greater Our our at has looking for Safety prior this this business the grown business Biologic EBITDA basis, expanding This growth in ELISA our year-to-date XX%
in we for CAP scaled process-related exciting and as along for CDMO and including measuring channel Lastly, we the the HCP sales especially serve BSA impurities. significantly, -- channel continue is market to GTP offerings, both manufacturing, we're growing reflect customer demand segments endonuclease continue ELISA ELISAs evolutions for broader through direct seeing SfX This growth XXX, partners. the and ELISA, HCP broader our with up our through with other AAV HEK
which X% EBITDA the of and in less expenses Our the we the were $X.X Detection to September, for at that revenues million Protein business, less of were adjusted levels our not million quarter Thompson in totals represented X% than Corporate $XX.X segment-related EBITDA. million. than quarter, Street early $X from XXXX QX divested the included of flat in adjusted relatively
in full of $XXX raising updated a our are year, estimating $XX.X midpoint year at XXXX which guidance we increase Now our $XXX our now guidance. to CleanCap our XXXX XXXX the XX for COVID-XX guidance at revenues $XXX million to Slide prior estimate vaccine $XXX Included $XXX million range our our for revenue to is directly our million, million up the to $XX.X prior million the overall $XXX attributable up total revenue we million are customers, and midpoint. million at moving million, to from to from guidance. Today,
of guidance full Testing that contribution, modest also XX% for of XXXX will guidance divestiture the As at for total reported the annual year the the growth expectation reflects Detection the which revenue XXXX. of $XX Protein of reflects the Biologic business, revenue million this for business Safety loss and remain our around
relatively will that at the contribution results to be are we revenues Maravai planning million XXXX. within Production segment. whole, as Detection Acid of $XXX for forma small around a total Nucleic updated on not midpoint Protein This about Given the presenting the this implies pro guidance segment
our gene companies Further, CleanCap therapy with cell vaccine fueling as growth. opportunity as and platforms We're coming of excited including key the and traction here non-COVID validation as for programs new the mRNA blue-chip of very about customer as initial of from continue orders foreseeable to across see rapid good mRNA future. major We our and is extremely development outside a well to COVID-XX share, momentum platform for development. demand exciting base offering our segment an busy as role to a represent contributor these long-term mid- strong the
therapeutic on may that our As our part the On for supported purchase of in forecast quarters orders, out near GMP discussed suites which binding customers term extend last by our builds a for further are for acid large support used top have of several those largest metrics. forecasts rolling other a be on forecast guidance programs. but on revenue to months. based expectations, for is revenue in we comes guidance call, visibility are we and guidance for our that degree fluctuations. several that, revenue out our forward still some considerable to go funnel these and on to our our Based here with customers' subject certain nucleic financial mainly our factors, may key internal Based have updated quarterly
our of non-GAAP measure adjusted million, range. a in midpoint the $XXX the be of our expect of of midpoint the million the at prior and EBITDA year represents $XXX non-GAAP We to, margin at XXXX which XX% EBITDA, range of the implied percentage an over XXX% revenue growth to range adjusted
around range highlighted to continuing our implies EPS, overall $X.XX expand non-GAAP base we $X.XX meet EPS to to is revenue here to Adjusted measure, look investments in $X.XX be of record expansion. our fully are tied expected quarter our to demand. for to to is commercial make in the customer directly margin $X.XX organic we As in share. organizations, growth and guidance we've to last for and per per call, the our and of diluted continue share XXXX. fourth The R&D This of employees increase our a in
XX. Slide in to assumption shares, diluted A fully results are Class the diluted of fully to XXX around full to A Class adjusted count the been XXXX. as included net million of noncontrolling our Class for B all any converted B EPS share of that income based diluted Adjusted to to shares. adjusted shares on result year million to a in eliminate XXX is the forecasted move fully a Class Let's net loss shares of full The attributable income EPS has conversion or which interests
based adjustments that rate on diluted on to Additionally, distribution some including range core an XX%. effective revenue reflect based our rate tax fully The reflecting of growing do our our of the EPS, adjusted certain geographical not operations, adjusted forecast tax effective base. are improvement XX%
which Interest our certain the As and adjusted in million we than invest total million $XX $XX compensation, non-GAAP non-GAAP to expense and And to we it to and adjustments million. $XX an to adjusted million; million; EBITDA needed item reconciling to show $XX between see X% $XX XX%; GAAP to relates the million for to an less a capital EBITDA, expect tax as estimated other $XX of amortization following XXXX, million revenues. between be $XX of we between range, get rate to and items for depreciation million $XX expenditures, XXXX: equity-based XX% from
income then net of in and adjusted to our GAAP is EBITDA reconciliation EBITDA presented today. EBITDA GAAP to press from Our release
segment-related our our detailed days. will in addition, be information to plan In Form coming we the in file which XX-Q,
to Slide XX. turning Now
revenue our see initial You'll XXXX. for expectations calendar
based do we provide While on we call, current on provide year our call, at always $XXX guidance of the when XXXX Protein did $XXX want nor to growth third XX% don't line business. our guidance this the for detailed a of top the precedent set midpoint to from Detection provide our of to divestiture on major orders implies quarter of adjusted guidance million on to view Revenue the intend future in want we XXXX our customers. initial for million to
XXXX see XX% demand for increasing XXXX in As between level. X% Carl we mentioned, COVID the vaccines over CleanCap and
part annual we As to guidance first components next XXXX detailed the provide year. for more other it of to guidance, relates plan of in will
financial third was another quarter operational, Our strategic of quarter solid and execution.
on business, products businesses. our with their to support core support focus organic time support and continue COVID demand, on grow quality customers vaccine the We expansion to our strong
also products. solid to back Now Carl, want support supply chain state to our call remains our of before that I turn I in the
issues. us positioned Our with systems investment in our quality business chain supply well continuity have present for no our activities and
a series have only their that of our logistic been of have with bases. fortunate and vendor These global and from which also purchases relationships built strong period been are XX% long U.S.-based deepened companies company that have sourced the U.S., We from Maravai legacy inventory customer risks. the and of in over supply our mitigates relationships ownership. acquisitions has year-to-date
stable here of and clearly gene position. forward base that see of my to strong it's looking an over industry-leading XXXX, the strong As EBITDA wrapping services. flexible innovation of continued year segments, reshape flow balance we and and in capacity across and we on to drive cell a a to look margins, expansion Maravai growth our are next the and eyes R&D long-term X markets, to a XXXX is Combine sheet customers and items To with increase ever-increasing customers those growth. that up products with our weeks continue our remarks, of primed to a ready and focus key activities, a to vaccine suite support team therapy and is turn conclude investment core in and focused, evident free cash great
on final XX. I'll Now turn back for some to it Carl remarks Slide
